ChromaDex Announces Agreement with Glanbia Nutritionals
This past week, ChromaDex Corporation (OTCBB: CDXC) announced a distribution agreement with Glanbia Nutritionals (NA) Inc. for its patented brand of pterostilbene, pTeroPure. Under the agreement, Glanbia will serve as the sole distributor of pTeroPure in North America.
Pterostilbene is an ingredient found in berries, most abundantly in blueberries, which is believed to contain several health benefits. The natural ingredient gained notoriety after the patented pTeroPure was named the 2010 North American Most Promising Ingredient of the Year by the independent company Frost & Sullivan. The ingredient is notable for its “superior biological activity, better oral availability, and metabolizes more slowly in the body.”
After conducting the first ever human trial with the ingredient at the University of Mississippi, the results indicated pTeroPure compound was safe for human consumption. Researchers are continuing to analyze effects on blood pressure, triglycerides, cholesterol, and oxidative stress, and any additional health benefits or other discoveries that are made will be published in a peer-reviewed journal later this year.
"As an innovative ingredient with impressive scientific support, pTeroPure is an excellent addition to our current product line," said Richard Hazel, CEO of Glanbia Nutritionals. "We're excited to work with ChromaDex to increase their current market presence and introduce pTeroPure into new applications and territories."
CEO and Founder of ChromaDex, Frank Jaksch, also expressed his excitement concerning the Glanbia agreement. “With our recently announced pTeroPure clinical safety results and the forthcoming human efficacy data, Glanbia should be well positioned to bring our exciting novel patented and proven ingredient to the food & beverage, dietary supplement, and animal health markets."
About Glanbia Nutritionals (NA), Inc.:
Glanbia Nutritionals is a division of Glanbia plc, an international nutritional solutions and cheese group, headquartered in Kilkenny, Ireland. The Group has 4,300 employees worldwide, with operations in Ireland, the UK, Germany, USA, Canada, Mexico and China, as well as strategic international joint ventures in the UK, USA and Nigeria. Glanbia is listed on both the Dublin and London Stock Exchange. Glanbia is a global supplier of nutritional ingredients, functional ingredients and customized premix solutions. Glanbia Nutritionals is on the forefront in the exploration of science and the dynamics that drive the growing nutrition industry. For more information visit www.glanbianutritionals.com or contact Thomas Monroe, Marketing, 760-438-0089, firstname.lastname@example.org.
ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. ChromaDex's pipeline of proprietary products include patented pTeroPure® pterostilbene, which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company, Frost & Sullivan. The company has also launched ProC3G™, a natural black rice extract containing 40% cyanidin-3-glucoside and is in the process of developing Nicotinamide Riboside, a novel next-generation B-vitamin. All products are backed with extensive scientific research and intellectual property.
Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies' filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
ChromaDex Investor Contact:
The Del Mar Consulting Group, Inc. Robert B. Prag, President 858-794-9500 email@example.com
or Alex Partners, LLC Scott Wilfong, President 425- 242-0891 Scott@alexpartnersllc.com